-
Sector Analysis
OpportunityAnalyzer: Idiopathic Pulmonary Fibrosis – Opportunity Analysis and Forecast to 2025
The IPF therapeutic market is currently dominated by the only two drugs that have gained marketing approval for IPF – Roche's Esbriet and Boehringer Ingelheim's Ofev. Esbriet was the first drug to gain approval for IPF in 2011 when it was approved for use in Europe, a full four years before rival Ofev. However, both gained approval into the largest IPF market of the US on the same day in October 2014. The top-selling drug in IPF in value terms...
-
Track & Monitor
Partnerships, Licensing, Investments and M&A Deals and Trends for June 2016 in Pharmaceuticals
GlobalData's “Partnerships, Licensing, Investments and M&A Deals and Trends for June 2016 in Pharmaceuticals” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in June 2016. The report portrays detailed comparative data on the number of deals and their value in the last...